albendazole has been researched along with Loiasis in 24 studies
Loiasis: A parasitic infection caused by the nematode Loa loa. The vector in the transmission of this infection is the horsefly (Tabanus) or the deerfly or mango fly (Chrysops). The larvae may be seen just beneath the skin or passing through the conjunctiva. Eye lesions are not uncommon. The disease is generally mild and painless.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because of the life-threatening, post-treatment reactions that have occurred in patients with loiasis treated with ivermectin, evaluation of a short-course albendazole regimen was undertaken in a Loa-endemic region of Cameroon." | 9.11 | Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. ( Befidi-Mengue, R; Fogako, J; Folefack, A; Fualem, R; Gwanmesia, P; Horton, J; Leke, R; Nutman, TB; Pensia, E; Quakyi, I; Tabi, TE, 2004) |
| "To assess the filaricidal activity and clinical safety of albendazole in human loiasis, a double-blind, placebo-controlled study was conducted in an endemic area in Benin, Africa." | 9.07 | Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. ( Ahouissou, NL; Ekoué, S; Horton, J; Klion, AD; Lanmasso, T; Massougbodji, A; Nutman, TB, 1993) |
| "Although diethylcarbamazine is curative in approximately 60% of patients who acquire loiasis as long-term visitors to an endemic area, some individuals continue to have signs and symptoms of infection despite multiple courses of diethylcarbamazine." | 7.70 | Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. ( Horton, J; Klion, AD; Nutman, TB, 1999) |
| "Loiasis is a vector-borne parasitic infection endemic across many areas of Central and West Africa." | 5.56 | Encephalopathy in a patient with loiasis treated with albendazole: A case report. ( Biliotti, E; De Angelis, M; Di Bonaventura, C; Franchi, C; Gabrielli, S; Mattiucci, S; Morano, A; Taliani, G; Volpicelli, L, 2020) |
| "Sixty men and women from a loiasis endemic area in Cameroon were randomized after stratification by screening LLM (≤ 30000, 30001-50000, >50000) to three treatment arms: two doses albendazole followed by 4 doses matching placebo (n = 20), six doses albendazole (n = 20) albendazole or 6 doses matching placebo (n = 20) administered every two months." | 5.22 | Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial. ( Gounoue, R; Kamgno, J; Kuesel, AC; Nguipdop-Djomo, P; Téjiokem, M, 2016) |
| "Because of the life-threatening, post-treatment reactions that have occurred in patients with loiasis treated with ivermectin, evaluation of a short-course albendazole regimen was undertaken in a Loa-endemic region of Cameroon." | 5.11 | Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. ( Befidi-Mengue, R; Fogako, J; Folefack, A; Fualem, R; Gwanmesia, P; Horton, J; Leke, R; Nutman, TB; Pensia, E; Quakyi, I; Tabi, TE, 2004) |
| " A trial was therefore conducted to evaluate whether a course of albendazole would bring about a slower decrease in the Loa microfilaraemia, and thus could be used as a mass 'clearing' treatment, before the distribution of ivermectin in areas where onchocerciasis and loiasis are co-endemic." | 5.10 | Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. ( Boussinesq, M; Kamgno, J; Moyou-Somo, R; Pion, SD; Tsague-Dongmo, L, 2002) |
| "To assess the filaricidal activity and clinical safety of albendazole in human loiasis, a double-blind, placebo-controlled study was conducted in an endemic area in Benin, Africa." | 5.07 | Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. ( Ahouissou, NL; Ekoué, S; Horton, J; Klion, AD; Lanmasso, T; Massougbodji, A; Nutman, TB, 1993) |
| "Our findings strongly support WHO's provisional strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and ivermectin cannot be safely mass administered." | 3.85 | Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. ( Boussinesq, M; Chesnais, CB; Fischer, PU; Missamou, F; Pion, SDS; Weil, GJ, 2017) |
| "Although diethylcarbamazine is curative in approximately 60% of patients who acquire loiasis as long-term visitors to an endemic area, some individuals continue to have signs and symptoms of infection despite multiple courses of diethylcarbamazine." | 3.70 | Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. ( Horton, J; Klion, AD; Nutman, TB, 1999) |
| "Loiasis has been associated with excess mortality, but clinical studies on its treatment are scant, particularly outside endemic areas, due to the rarity of cases diagnosed." | 2.87 | Comparison of different drug regimens for the treatment of loiasis-A TropNet retrospective study. ( Angheben, A; Bisoffi, Z; Bottieau, E; Bouchaud, O; Buonfrate, D; Calleri, G; Clerinx, J; Gobbi, F; Guerriero, M; Herrera-Ávila, JP; Neumayr, A; Rodari, P; Rojo-Marcos, G; Rothe, C; Salvador, F; Treviño, B; Zammarchi, L, 2018) |
| "Loiasis is a vector-borne parasitic infection endemic across many areas of Central and West Africa." | 1.56 | Encephalopathy in a patient with loiasis treated with albendazole: A case report. ( Biliotti, E; De Angelis, M; Di Bonaventura, C; Franchi, C; Gabrielli, S; Mattiucci, S; Morano, A; Taliani, G; Volpicelli, L, 2020) |
| " When distributing microfilaricides however, considerable care is needed to minimise the risk of severe adverse events (SAEs) in areas that are co-endemic for onchocerciasis or LF and loiasis." | 1.48 | Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. ( Basáñez, MG; Cano, J; O'Hanlon, SJ; Pullan, RL; Rebollo, MP; Tekle, AH; Wanji, S; Zouré, HG, 2018) |
| "Loiasis was diagnosed by means of positive IgG4 serology against Loa loa." | 1.32 | [A patient with loiasis following a trip to Central Africa]. ( Jaspers, CA; Sanders, CJ; van Kortenhof, NM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zoleko-Manego, R | 1 |
| Kreuzmair, R | 1 |
| Veletzky, L | 1 |
| Ndzebe-Ndoumba, W | 1 |
| Ekoka Mbassi, D | 1 |
| Okwu, DG | 1 |
| Dimessa-Mbadinga-Weyat, LB | 1 |
| Houtsa-Temgoua, RD | 1 |
| Mischlinger, J | 1 |
| McCall, MBB | 1 |
| Kresmner, PG | 1 |
| Agnandji, ST | 1 |
| Lell, B | 1 |
| Adegnika, AA | 1 |
| Mombo-Ngoma, G | 1 |
| Ramharter, M | 1 |
| Volpicelli, L | 1 |
| De Angelis, M | 1 |
| Morano, A | 1 |
| Biliotti, E | 1 |
| Franchi, C | 1 |
| Gabrielli, S | 1 |
| Mattiucci, S | 1 |
| Di Bonaventura, C | 1 |
| Taliani, G | 1 |
| Pion, SDS | 1 |
| Chesnais, CB | 1 |
| Weil, GJ | 1 |
| Fischer, PU | 1 |
| Missamou, F | 1 |
| Boussinesq, M | 3 |
| Peñafiel-Freire, DM | 1 |
| Herranz-Aguirre, M | 1 |
| Cano, J | 1 |
| Basáñez, MG | 1 |
| O'Hanlon, SJ | 1 |
| Tekle, AH | 1 |
| Wanji, S | 1 |
| Zouré, HG | 1 |
| Rebollo, MP | 1 |
| Pullan, RL | 1 |
| Gobbi, F | 2 |
| Bottieau, E | 1 |
| Bouchaud, O | 1 |
| Buonfrate, D | 2 |
| Salvador, F | 1 |
| Rojo-Marcos, G | 1 |
| Rodari, P | 1 |
| Clerinx, J | 1 |
| Treviño, B | 1 |
| Herrera-Ávila, JP | 1 |
| Neumayr, A | 1 |
| Calleri, G | 1 |
| Angheben, A | 2 |
| Rothe, C | 1 |
| Zammarchi, L | 1 |
| Guerriero, M | 1 |
| Bisoffi, Z | 2 |
| Tamarozzi, F | 1 |
| Degani, M | 1 |
| Metzger, WG | 1 |
| Mordmüller, B | 1 |
| Bulman, CA | 1 |
| Bidlow, CM | 1 |
| Lustigman, S | 1 |
| Cho-Ngwa, F | 1 |
| Williams, D | 1 |
| Rascón, AA | 1 |
| Tricoche, N | 1 |
| Samje, M | 1 |
| Bell, A | 1 |
| Suzuki, B | 1 |
| Lim, KC | 1 |
| Supakorndej, N | 1 |
| Supakorndej, P | 1 |
| Wolfe, AR | 1 |
| Knudsen, GM | 1 |
| Chen, S | 1 |
| Wilson, C | 1 |
| Ang, KH | 1 |
| Arkin, M | 1 |
| Gut, J | 1 |
| Franklin, C | 1 |
| Marcellino, C | 1 |
| McKerrow, JH | 1 |
| Debnath, A | 1 |
| Sakanari, JA | 1 |
| Kamgno, J | 3 |
| Nguipdop-Djomo, P | 1 |
| Gounoue, R | 1 |
| Téjiokem, M | 1 |
| Kuesel, AC | 1 |
| Moliner, JV | 1 |
| Valverde, AG | 1 |
| Sorolla, JM | 1 |
| Sgrelli, A | 1 |
| De Socio, GV | 1 |
| Papili, R | 1 |
| D'Annibale, ML | 1 |
| Baldelli, F | 1 |
| Morrone, A | 1 |
| Franco, G | 1 |
| Toma, L | 1 |
| Tchangmena, OB | 1 |
| Marangi, M | 1 |
| Tsague-Dongmo, L | 1 |
| Pion, SD | 1 |
| Moyou-Somo, R | 1 |
| van Kortenhof, NM | 1 |
| Jaspers, CA | 1 |
| Sanders, CJ | 1 |
| Tabi, TE | 1 |
| Befidi-Mengue, R | 1 |
| Nutman, TB | 3 |
| Horton, J | 3 |
| Folefack, A | 1 |
| Pensia, E | 1 |
| Fualem, R | 1 |
| Fogako, J | 1 |
| Gwanmesia, P | 1 |
| Quakyi, I | 1 |
| Leke, R | 1 |
| Stemmle, J | 1 |
| Markwalder, KA | 1 |
| Zinkernagel, AS | 1 |
| Wirth, MG | 1 |
| Grimm, F | 1 |
| Hirsch-Hoffmann, S | 1 |
| Thiel, MA | 1 |
| Franco-Alvarez de Luna, F | 1 |
| Giménez-Almenara, G | 1 |
| Vidal, E | 1 |
| Casal, M | 1 |
| Klion, AD | 2 |
| Massougbodji, A | 1 |
| Ekoué, S | 1 |
| Lanmasso, T | 1 |
| Ahouissou, NL | 1 |
| Blum, J | 1 |
| Wiestner, A | 1 |
| Fuhr, P | 1 |
| Hatz, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Host Response to Infection and Treatment in the Filarial Diseases of Humans[NCT00001230] | 500 participants (Anticipated) | Observational | 1991-03-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for albendazole and Loiasis
| Article | Year |
|---|---|
Loa loa-does it deserve to be neglected?
Topics: Albendazole; Diethylcarbamazine; Filaricides; Humans; Ivermectin; Loiasis | 2014 |
[Loa loa filariasis in Italy: review of the literature with a clinical report].
Topics: Adult; Albendazole; Animals; Antinematodal Agents; Diethylcarbamazine; Diptera; Drug Therapy, Combin | 2011 |
7 trials available for albendazole and Loiasis
| Article | Year |
|---|---|
Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.
Topics: Adult; Albendazole; Animals; Clinical Protocols; Fishes; Gabon; Humans; Ivermectin; Loiasis | 2023 |
Comparison of different drug regimens for the treatment of loiasis-A TropNet retrospective study.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Europe; Filaricides; Humans; Ivermectin; Loa; Loias | 2018 |
Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial.
Topics: Adolescent; Adult; Aged; Albendazole; Anthelmintics; Cameroon; Double-Blind Method; Female; Humans; | 2016 |
Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cameroon; Child; Drug Administration Schedule; Female | 2002 |
Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Anthelmintics; Cameroon; Cross-Over Studies; Double-B | 2004 |
Albendazole in human loiasis: results of a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Africa, Western; Aged; Albendazole; Double-Blind Method; Female; Humans; Loiasis; | 1993 |
Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Dietary Fats; Female; Filaricides; Humans; Loa; Loia | 2002 |
15 other studies available for albendazole and Loiasis
| Article | Year |
|---|---|
Encephalopathy in a patient with loiasis treated with albendazole: A case report.
Topics: Adrenal Cortex Hormones; Adult; Albendazole; Animals; Diagnosis, Differential; Filaricides; Guinea; | 2020 |
Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.
Topics: Adolescent; Adult; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Child; Elephantiasis, | 2017 |
Loiasis, a Subconjunctival Manifestation.
Topics: Albendazole; Animals; Anthelmintics; Child; Conjunctivitis; Drug Therapy, Combination; Eye Infection | 2017 |
Global programme to eliminate lymphatic filariasis: progress report, 2016.
Topics: Albendazole; Anthelmintics; Diethylcarbamazine; Disease Eradication; Drug Therapy, Combination; Elep | 2017 |
Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
Topics: Africa South of the Sahara; Albendazole; Animals; Diethylcarbamazine; Drug Synergism; Drug Therapy, | 2018 |
Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy.
Topics: Adolescent; Adult; Aged; Albendazole; Antiprotozoal Agents; Biomarkers; Communicable Diseases, Impor | 2019 |
Meeting of the International Task Force for Disease Eradication, January 2014.
Topics: Advisory Committees; Africa; Albendazole; Anthelmintics; Disease Eradication; Elephantiasis, Filaria | 2014 |
Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
Topics: Adult; Albendazole; Animals; Anthelmintics; Auranofin; Brugia malayi; Cattle; Cell Line; Diethylcarb | 2015 |
[Loa loa meningoencephalitis secondary to treatment with mebendazol].
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Brain Damage, Chronic; Central Nervous System Helmi | 2011 |
A case of loiasis in Rome.
Topics: Adult; Albendazole; Anthelmintics; Anti-Inflammatory Agents; Betamethasone; Diagnosis, Differential; | 2002 |
[A patient with loiasis following a trip to Central Africa].
Topics: Albendazole; Animals; Antibodies, Helminth; Cameroon; Diagnosis, Differential; Edema; Eosinophilia; | 2003 |
[Loa loa infection of the eye -- a case series].
Topics: Adolescent; Adult; Albendazole; Animals; Cameroon; Combined Modality Therapy; Conjunctiva; Eye Infec | 2005 |
[Patient from the Republic of Congo with intermittent ocular pain].
Topics: Adult; Albendazole; Animals; Anthelmintics; Congo; Conjunctiva; Conjunctival Diseases; Humans; Loa; | 2007 |
Albendazole therapy for loiasis refractory to diethylcarbamazine treatment.
Topics: Adult; Albendazole; Anthelmintics; Diethylcarbamazine; Drug Resistance; Female; Filaricides; Humans; | 1999 |
Encephalopathy following Loa loa treatment with albendazole.
Topics: Albendazole; Animals; Anthelmintics; Blood Chemical Analysis; Delirium; Electroencephalography; Ence | 2001 |